Augustine follows up venture round with pair of C-suite hires

Weeks after closing a €78 million ($85 million) series A round to support development of a pipeline of HDAC6 inhibitors, Belgium-based Augustine Therapeutics N.V. has added two new executives to its C-suite. Virginie Cartage, formerly the CFO of Novadip Biosciences S.A., is joining as CFO. Andy Hu, a former colleague of Augustine CEO Gerhard Koenig at Arkuda Therapeutics Inc., will be Augustine’s CBO.

Cidara Therapeutics Inc. (NASDAQ:CDTX) formally promoted Nicole Davarpanah to CMO. She had held the role on an interim basis since Taylor Sandison’s departure in February; her previous title was SVP of translational R&D. Cidara, which last year reacquired full rights to drug-Fc conjugate CD388 to treat influenza A and B as part of a strategic shift, also promoted VP of Clinical Development Corinna Pavetto to SVP of clinical development...